Initiate Phase 2 development program with RP2/3
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Aug 2022
- Due
- 31 Mar 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company remains on track to initiate its Phase 2 development program with RP2/3 in the first quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company failed to initiate the Phase 2 program by the Q1 2023 deadline, subsequently pushing the expected initiation date to mid-year 2023 in filings dated after the original deadline.
-
A Replimune Group, Inc. 10-K filed 2023-05-18
“We continue to plan for our previously announced Phase 2 development program for RP2 and/or RP3 that we expect to initiate around mid-year 2023.” ✓ confirmed on the page
Market reaction: the shares moved +0.2% against the S&P 500 over the three sessions around the disclosure (17 May 2023 to 22 May 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 3 versions
-
Version 1 · original · stated 4 Aug 2022
Deadline 31 Mar 2023 (“first quarter of 2023”) · wording firm
-
Version 2 · stated 3 Nov 2022
Deadline 30 Jun 2023 (“first half of 2023”) · wording expected
“The Company expects to initiate its Phase 2 development program with RP2/3 in the first half of 2023.”
-
Version 3 · stated 7 Dec 2022
Deadline 30 Jun 2023 (“in the first half of 2023”) · wording firm
“Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- RP2/3 Phase 2 development program
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002688 · Corrections policy